Form 4: Ocular Therapeutix Executive Sells Shares for Tax Obligations

Ocular Therapeutix's Executive Chairman, President, and CEO, Pravin Dugel, sold 21,494 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Pravin Dugel, Executive Chairman, President, and CEO of Ocular Therapeutix, Inc. (OCUL), reported a sale of common stock.
• A total of 21,494 shares of common stock were sold on August 25, 2025.
• The shares were sold at a weighted average price of $12.04 per share, with individual transactions ranging from $11.89 to $12.18.
• The sale was executed pursuant to a durable automatic sale instruction (Rule 10b5-1 plan) adopted on February 21, 2024.
• The purpose of the sale was to satisfy tax withholding obligations in connection with the vesting of restricted stock units (RSUs) on August 22, 2025.
• The transaction was non-discretionary, meaning it was not a personal investment decision at the time of sale.
• Following the transaction, Pravin Dugel directly beneficially owns 3,227,244 shares of common stock.
• Additionally, 250,361 shares are indirectly beneficially owned by the Pravin Dugel 2024 Irrevocable Trust.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary insider sale for tax purposes related to RSU vesting, executed under a pre-arranged 10b5-1 plan. This is a neutral event and does not indicate a change in the executive's sentiment towards the company.

Future Outlook

No forward-looking statements or guidance are provided in this insider transaction report.

Management Comments

• The sales do not represent a discretionary trade by the reporting person.

Industry Context

This filing is a routine insider transaction report and does not provide information related to broader industry trends or competitors.

Stakeholder Impact

• Shareholders: Minimal impact as this is a routine, non-discretionary sale for tax purposes and does not signal a change in the executive's confidence or company fundamentals.

Key Dates

Recommendation

The reported transaction is a non-discretionary sale by an executive to cover tax obligations associated with RSU vesting, executed under a pre-arranged Rule 10b5-1 plan. This is a routine event and does not reflect a change in the executive's view on the company's prospects, thus it does not warrant a change in investment recommendation.

Keywords

OCULAR THERAPEUTIX, OCUL, Form 4, insider trading, stock sale, Pravin Dugel, RSU, restricted stock units, 10b5-1 plan, tax withholding